News

Following the acquisition, R5 is expected to retain its current identity and brand and will become a subsidiary of Aesica Pharmaceuticals. Aesica Pharma said that the capability and

Clinuvel Pharma claimed that it had to develop new study methodology along with EPP experts to be able to evaluate Scenesse, in this 12 month European and Australian

RXi Pharma is expected to use the fund for pre-clinical development of RNAi therapeutics using its novel, proprietary therapeutic platform, which includes both novel RNAi compounds and advanced

Supernus expects to enroll 50 subjects in the study at 5 sites across the US. Supernus Pharma claimed that SPN812 is one of three compounds being developed by

Iowa Health said that Greenway was selected for its $21.7m program by the New York City REC, administered by the NYC Regional Electronic Adoption Center for Health (NYC

Fredericksburg said that the trial, supported by the National Cancer Institute (NCI) to evaluate treatment for metastatic (advanced stage) melanoma, is expected to enroll 148 patients across the

The KCI ART is expected to investigate emerging medical therapies and technologies to fuel product development and commercialisation. The ART will focus on conducting applied research to develop

Making use of HighRes dual NanoCell system, which includes two AmbiStore high-speed carousels of HighRes, Rigel is expected to perform cell-based, biochemical, and high-content screening assays against a

With the completion of the localisation, the program is expected to include both the English and Greek versions of GeneMedRx rely to analyse complex medication regimens and DNA